Results 191 to 200 of about 21,696 (215)

Rechallenge of ruxolitinib after momelotinib-related toxicity in a 74-yo woman with secondary myelofibrosis: a case report. [PDF]

Front Med (Lausanne)
Torregrosa Diaz JM, Cailly L, Gallego Hernanz MP, Gardeney H, Cayssials E.   +4 more
europepmc   +1 more source

JAK Inhibitors for Treatment of Pyoderma Gangrenosum and Sweet Syndrome: A Systematic Review of Published Case Reports. [PDF]

Dermatol Res Pract
Vahabi SM, Heidari S, Farahmand Y, Pourgholi E, Kianfar N, Memari H, Esmaeili F, Bahramian S, Etesami I, Ansari MS.   +9 more
europepmc   +1 more source

JAK and MEK Pathway Regulation of Mitochondrial Activity as Possible Targets for Saphenous Vein Smooth Muscle Cell Dysfunction in Diabetes. [PDF]

Cells
Bolanle IO, Moshapa FT, Durham GA, Hobkirk JP, Riches-Suman K, Loubani M, Sturmey RG, Palmer TM.   +7 more
europepmc   +1 more source

Hotspots and Emerging Trends in JAK Inhibitor Therapy for Vitiligo: A Bibliometric Analysis (2015-2025). [PDF]

J Inflamm Res
Peng Y, Feng J, Lu L, He H, Xie A, Zhang S, Yang L, Liu Y, Wang T.   +8 more
europepmc   +1 more source

A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis [PDF]

Cancers, 2023
Most patients with myelofibrosis (MF) discontinue ruxolitinib (JAK1/JAK2 inhibitor) in the first 5 years of therapy due to therapy failure. As the therapeutic possibilities of MF are expanding, it is critical to identify patients predisposed to early ...
Elisabetta Abruzzese, Elena Maria Elli, Nicola Polverelli   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval

Annals of Hematology, 2021
Shreekant Parasuraman, Jingbo Yu, Claire N Harrison   +2 more
exaly  

Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis

Frontiers in Immunology, 2022
Xiao-Dong Mo, Shuang Fan, Meng-Zhu Shen
exaly